We are living in an age where there are many possibilities for a drug for to combat the symptoms of Huntington’s disease (HD). It is an exciting time for the HD community around the world and my HOPE is at a new level.
Another drug that silences the mutant huntingtin gene, is AMT-130 developed byuniQure. (uniQure’s gene therapy) AMT-130 involves a harmless virus packaged with genetic material that is designed to lower the amount of huntingtin protein in the brain. AMT-130 is delivered via a single surgery into the brain, with the goal of permanently lowering levels of huntingtin in nerve cells.
In July 2024, uniQure announced promising interim data demonstrating slowing of disease progression in our ongoing Ph. I/II clinical trials.
These type of drugs, that control symptoms of HD, will help HD families have a higher quality to their lives.
Another Huntington’s Disease (HD) promising drug, pridopidine, a pill, could improve quality of life for people by preserving their independence. HD often include slight disruptions in someone’s ability to perform day-to-day activities, such as handling their finances, remembering directions, and managing household chores.
HD clinicians often use a rating scale to measure “Total Functional Capacity” (TFC), which encompasses many aspects of someone’s capacity to live and function independently.
Prilenia’s drug, pridopidine, supports total functional capacity in people with HD. “PROOF-HD marks the first time in HD that we have had a study suggest benefit on multiple important clinical measures, including progression, cognition, and motor findings,” said North American investigator Andrew Feigin.
I’m continuing to share exciting news on Huntington’s disease (HD) drugs that could potentially hold the key to a higher quality of life for Huntington’s Disease (HD) patients/families. The next promising drug is PTC-518.
On June 20, 2024, Huntington’s Disease Society of America (HDSA) received an update from PTCTherapeutics about their ongoing trial, PIVOT-HD. PIVOT is testing PTC-518, a small molecule drug, taken as a pill, that lowers huntingtin (HTT) in people with Huntington’s disease (HD).
Dr. Sarah Hernandez, editor-in-chief at HDBuzz.net states, “We know that the genetic cause of HD is an expansion of the genetic code within the HTT gene. There’s an extra bit of genetic message that repeats the letters C, A, and G more times than it should. When someone has 40 or more CAG repeats in their HTT gene, they’ll go on to develop HD, unless researchers can find some way to intervene.”
What does the HTT gene do? The HTT gene provides instructions for making a protein called huntingtin.
Over the next few months, I will report on five positive clinical trials being conducted around the world for Huntington’s disease (HD)who’s drug could potentially hold the key to a higher quality of life for HD patients/families.
“The stormy trial updates that hung over the Huntington’s disease field in 2021 have certainly parted, making way for the bright and clear forecast we’ve had so far in 2024!” Dr. Rachel Harding.
“Sage has been working on an experimental therapy called dalzanemdor. The drug acts on NMDA receptors, which help to transmit chemical messages between nerve cells. There is an imbalance in this messenger system across many diseases, which causes changes in thinking and memory. Dalzanemdor is a type of drug designed to boost the messages passed by NMDA receptors – it’s a bit like giving your brain cells a megaphone.”
“Overall, Sage’s recent press release about the SURVEYOR trial suggests dalzanemdor is generally safe. And perhaps more importantly, it suggests we have a robust way to measure cognition in HD with the HD-CAB. ”
The San Francisco Bay Area Chapter has a new volunteer, a freelance writer, Marisol Guzman, who is interviewing local families and writing their Huntington’s disease (HD) story. She then submits the article to media outlets in the Bay Area. This is a new outreach project for the Chapter, human interest stories, to heighten awareness of this devastating disease. The article is on my blog because it’s important to have the article appear on the Chapter’s social media platforms. The following is Marisol’s first article.
The Biggest Gambleby Freelance Writer, Marisol Guzman
Therese had life planned out. She couldn’t wait to graduate from college, get a job, marry John Marin, and start a family. John and his sisters Lora, Marcia, and Cindy were all close in age. Therese and the Marin siblings enjoyed partying and being young. The life ahead of this close-knit family was bright.
Phyllis Marin
However, Therese often wondered what had become of John’s mother: Phyllis Iva. None of the siblings could remember why mom was in a state hospital and what led to her young death. The father refused to share the big family secret. Therese had no idea how this family secret would be akin to opening Pandora’s box.
“When I first heard of Huntington’s Disease, I didn’t know what it was but I knew it was bad,” Therese recalls. The Marin sisters, John and her gathered to discuss their mother’s cause of death: complications from Huntington’s.
Huntington’s Disease (HD) is “a progressive degeneration of nerve cells in the brain that affects movement, cognitive functions, and emotions.” HD is often described as having the symptoms of Parkinson’s, Alzheimer’s and ALS simultaneously that strikes young. It’s a rare genetic disease that currently has no cure.
Therese was internally conflicted. Do I start over and risk losing the love of my life or do I stay and take a gamble on a genetic disease impacting my family? Therese deliberated on her decision. With hope and naivete, Therese decided to stay with John. Together they lived their lives as fully as possible before HD’s unpredictability interrupted their plans.
Lora was the oldest of the Marin children. At age five, she stepped up and became a mother figure to her siblings during her mom’s absence. HD psychologically affected Lora which manifested into deep depression that led to self-medicating with alcohol. This maladaptive coping behavior led to a decline in her marriage, and at 41 she died of a cerebral hemorrhage.
Marcia was the second oldest Marin sibling. The AT&T professional was a stylish and unassuming woman. Things started taking a turn when Marcia began to wobble in her high heels at work. Her coworkers assumed that she was coming to work drunk. In Marcia’s case, HD manifested itself with involuntary movements, unsteady gait, swallowing problems. Marcia stayed independent on her HD journey with help from Therese managing her care. Marcia died at 49 of a heart event.
Cindy was the second youngest in the family. Therese describes Cindy as a free spirit and quintessential flower child. Cindy led an athletic and adventurous lifestyle full of kayaking and backpacking through countries around the world. Through her active lifestyle, Cindy was able to slow down HD and didn’t start noticing symptoms until her early 40s. As HD progressed, she developed dystonia, difficulty swallowing and cognitive decline. Cindy died at age 54 of cardiovascular complications.
John and Therese watched his older sisters lose their battles to HD. There was unspoken anxiety of not knowing if John would be next. A test for HD was not developed until 1993. In 2016, John tested to know for certain whether HD would affect his two children as they were starting to build lives of their own. The family breathed a sigh of relief when John received a negative test result.
Although HD still has no cure, Therese holds hope in her heart that she will see a cure in her lifetime. For now, Therese is comforted knowing there are many pharmaceutical, biotech and therapeutic companies conducting clinical trials on drugs that will manage HD symptoms allowing HD patients to have a higher quality of life.
Therese Crutcher-Marin is President of HDSA San Francisco Bay Area Chapter, a Huntington’s disease advocate, and author and a blogger. Visit theresecrutchermarin.com
The 6th Annual San Jose Team Hope 10K Timed Run & 5K Walk was an awesome event raising approximately $22,300.00!!!!
The San Francisco Bay Area Chapter couldn’t have done it without a team effort by all the volunteers who helped with outreach for sponsors, donations for the silent auction and raffle and day of event helper. Thank you to all who made it a success!
Of course, folks want to know how their donated dollars are spent by the nonprofit, Huntington’s Disease Society of America (HDSA). Donors to HDSA, desire to know that their money is helping HD patients/families across the U.S.
The pictures below are the programs and services provided by the HDSA Chapters and Affiliates fundraising efforts. (approximately 55 Chapters/Affiliates)
Locally, the SF Chapter supports: two in-person monthly support groups facilitated by social workers in Palo Alto and Berkeley and we support all the programs/services in the pictures. They are free to HD families/patients across the U.S.
The SF Chapter now has a part time social worker, Satve Ilango.
Of course, folks want to know how their donated dollars are spent by the nonprofit, Huntington’s Disease Society of America (HDSA). Donors to HDSA, desire to know that their money is helping HD patients/families across the U.S.
The pictures below are the programs and services provided by the HDSA Chapters and Affiliates fundraising efforts. (approximately 55 Chapters/Affiliates)
Locally, the SF Chapter supports: two in-person monthly support groups facilitated by social workers in Palo Alto and Berkeley and we support all the programs/services in the pictures. They are free to HD families/patients across the U.S.
The SF Chapter now has a part time social worker, Satve Ilango.
Registration and check in starts at 9 a.m. Saturday morning. There will be breakfast items, coffee, fruit, water and sports drinks. Also, we will have great raffle items and silent auction items.
Timed runners will start at 9:30 and walkers at 10:00. Wear your Team Hope Walk t-shirts and run/walk in solidarity with the Huntington’s Disease South Bay community.
Last year we had a lot of fun, a lot of tears and hugs as the participants run/walk to fight Huntington’s disease. 2023 Pictures: